Ioversol API Market Size, Share, Growth Trends, and Outlook 2025–2032

The Ioversol API market continues to demonstrate stable growth, reaching a market size of USD 177 million in 2023. According to the latest industry analysis, the market is projected to expand at a CAGR of 4.40% during the forecast period 2024–2032, reaching approximately USD 260.78 million by 2032. This growth is primarily driven by the rising demand for contrast agents in diagnostic imaging, particularly in CT scans and angiographic procedures.

Ioversol, as a non-ionic contrast agent, offers excellent safety and high diagnostic efficacy, making it widely adopted across radiology. Its low osmolality reduces patient discomfort while enabling clear visualization of organs and vessels, gaining strong acceptance among radiologists. As healthcare systems increasingly prioritize patient safety and diagnostic accuracy, Ioversol is expanding its market share as a key alternative to traditional contrast agents.

👉 Download FREE Sample Report

Market Overview & Regional Analysis

North America recorded a market size of USD 49.67 million in 2023 and is expected to grow at a CAGR of 3.77% through 2032. The region’s dominance is supported by advanced healthcare infrastructure, high adoption of contrast imaging technologies, and strong reimbursement policies for diagnostic procedures. The U.S. accounts for over 80% of regional consumption and plays a central role in R&D for contrast agents.

In Europe, Germany, France, and the UK are leading demand growth, supported by well-established radiology networks. Meanwhile, Asia-Pacific is the fastest-growing region, driven by expanding hospital networks in China and India, alongside government investments in medical imaging equipment. Notably, Japan serves as a major producer of Ioversol API, supplying high-quality pharmaceutical-grade products to domestic and global markets.

Key Market Drivers and Opportunities

The market is primarily driven by the rising global incidence of cardiovascular diseases and cancer, which fuel diagnostic imaging demand. Approximately 45–50% of Ioversol usage is in cardiovascular angiography, followed by neurological diagnostics (30%), with the remainder in urological and general diagnostic applications.

Emerging opportunities include the development of combination formulations and the expansion of point-of-care (POC) imaging in outpatient settings. Pharmaceutical companies are also advancing new formulations designed to minimize nephrotoxicity risk, broadening safe patient applications. In addition, the growing middle-class population in emerging markets is increasing access to advanced diagnostic services, further boosting market growth.

Challenges & Restraints

The Ioversol API market faces several challenges, including stringent regulatory approval requirements and the high costs associated with developing new formulations. Alternative diagnostic technologies, such as MRI that does not require contrast agents, represent competitive pressure. Concerns around contrast-induced nephropathy (CIN) also persist, leading to restricted use among high-risk patient groups.

Furthermore, the concentration of API manufacturing facilities in limited geographies creates supply chain vulnerabilities. Recent disruptions in the pharmaceutical supply chain have underscored the need for diversified sourcing strategies for critical components such as Ioversol.

Market Segmentation by Type

• Original Drug

• Generic Drug

👉 Download FREE Sample Report

Market Segmentation by Application

• Hospitals

• Clinics

Market Segmentation and Key Players

• Guerbet Group

• Brother Technology

• Stellite

Report Scope

This report provides a comprehensive analysis of the Ioversol API market from 2025–2032, covering:

• Sales value, sales volume, and revenue forecasts

• Detailed segmentation by type and application

• Profiles of key players (product specifications, production capacities, sales performance, revenue, pricing, and gross margins)

• Competitive landscape analysis and identification of key challenges

Additionally, the study incorporates insights from primary research with industry experts and executives, as well as secondary research using trade data, company reports, and industry publications. The combined quantitative and qualitative methodology ensures balanced market perspectives.

👉 Get Full Report Here

About 24chemicalresearch

Founded in 2015, 24chemicalresearch has rapidly established itself as a trusted leader in chemical market intelligence, serving over 30 Fortune 500 companies. We provide data-driven insights through rigorous research methodologies, focusing on key industry factors such as government policies, emerging technologies, and competitive landscapes.

• Plant-level capacity tracking

• Real-time price monitoring

• Techno-economic feasibility studies

With a dedicated team of researchers with over a decade of experience, we deliver actionable, timely, and high-quality reports to help clients achieve their strategic objectives. Our mission is to be the most trusted source of market insights in the chemical and materials industries.

International: +1(332) 2424 294 | Asia: +91 9169162030
Website: https://www.24chemicalresearch.com/
Follow us on LinkedIn: https://www.linkedin.com/company/24chemicalresearch